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Risk of cancer in Turkish patients after treatment
with TNF antagonists
SIR, There is conflicting evidence whether anti-TNF therapy offers
an increased cancer risk in rheumatological disorders. In this
study, we aimed to collect pilot data on a possible association
between anti-TNF agent use and development of neoplasms
among Turkish patients with various rheumatological conditions.
We conducted a nationwide survey pooling reported cases from
26 different rheumatology centers in Turkey. A total of 2199
patients (1247 females, 952 males, mean age: 41.8 13.9 yrs) were
reported. Among those patients, 943 had AS (1027.16 patient-
years) (mean age: 37.3 10.9 yrs), 931 RA (1145.14 patient-years)
(mean age: 49.1 12.7 yrs), 132 PsA (mean age: 43.6 12.5 yrs),
127 JCA (mean age: 23.8 10.9 yrs) and 66 other disorders
(62.14 patient-years) (mean age: 30.9 10.3 yrs). Nine-hundred
and twenty-three patients had been treated with etanercept
(1028.54 patient-years), 853 with infliximab (1014.68 patient-
years) and 259 with adalimumab (223.69 patient-years).
One-hundred and sixty-four patients had been treated with more
than one anti-TNF agent. We used standardized incidence ratios
(SIRs) as measures of relative risk were expected number were
taken from a regional cancer survey conducted in the Izmir
(Western Turkey) region.
Fifteen malignancies (13 solid cancers and 2 lymphoprolifera-
tive disorders) were observed (SIR¼ 1.26, 95% CI 0.70, 2.08).
Ten patients had been treated with etanercept (SIR¼ 2.3, 95% CI
1.10, 4.23), three with infliximab (SIR¼ 0.66, 95% CI 0.14, 1.92),
one with adalimumab (SIR¼ 0.62, 95% CI 0.02, 3.48) and one
with etanercept and then adalimumab. Eleven RA patients
(SIR¼ 1.36, 95% CI 0.68, 2.43), two AS patients (SIR¼ 0.66,
95% CI 0.08, 2.38) and two patients with other indications
developed cancer after anti-TNF agents. Among RA patients who
developed cancer, seven patients had been treated with etanercept
(SIR¼ 2.46, 95% CI 0.99, 5.06), two with infliximab (SIR¼ 0.64,
95% CI 0.02, 3.56), one with adalimumab (SIR¼ 0.75, 95%
CI 0.09, 2.72) and one with etanercept, and then switched to
adalimumab (Fig. 1).
The number of studies investigating a possible association
between the use of TNF alpha antagonists in RA patients and the
development of cancer have been published with inconclusive
results. Wolfe and Michaud [1] reported increased risk of
lymphoma in RA patients compared with the general population,
and the risk was greatest in patients treated with TNF-a
antagonists. In a previous study by a regional Swedish cohort,
Geborek et al. [2] suggested that the overall incidence of cancer is
not increased in patients treated with anti-TNF agents, while there
may be an increased risk of lymphomas in those patients
compared with RA patients treated with conventional agents.
However, in the national Swedish cohort, including the data of the
previous regional cohort, Askling et al. [3] could not find any
increased risk for lymphomas in RA patients treated with TNF
antagonists than other patients with RA. Setoguchi et al. [4]
compared the risk of haematological malignancies and solid
tumours in elderly RA patients from US and Canada who
received biologic agents as compared with those treated with
methotrexate. The authors found no significant increase in the risk
of cancers in biologic agent users. Chakravarty et al. [5] and Wolfe
and Michaud [6] demonstrated an increased risk of non-
melanoma and all skin cancers in patients with RA treated with
anti-TNF agents, respectively. In contrast to RA, disease-
associated cancer risk has been poorly explored in AS. Recently,
no overall increased risk for solid cancers or lymphomas were
found in AS [7, 8].
Our nationwide survey did not show an increased risk of cancer
associated with TNF antagonist use when data with etanercept,
infliximab and adalimumab were considered together. On the
other hand, there was an increase of cancer risk with etanercept
use when these agents were considered separately and this trend
was also present among RA patients taken as a separate group.
There was no evidence for increased neoplasm among the AS
patients.
Our study had several limitations: first, we did not re-confirm
the cancer diagnoses neither clinically nor by histology. Second we
did not seek information about the background risk factors for
cancer, such as smoking status, or family history. Third, the
comparator group for the cancer incidence represented only a
limited geographic area [9]. Lastly, the total number surveyed as
well as the number of cancer cases found is rather small to make
robust comparisons.
Our results, which need to be interpreted in the light of short-
comings of our survey we mention above, nevertheless suggest
that the risk of malignancy with the use of TNF antagonists might
differ in different disease states (i.e. RA, SpAs), and with the use
of different anti-TNF agents. Larger prospective collaborative
studies with prolonged follow-up and more meticulous methodol-
ogy will be needed in order to obtain more precise estimates.
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FIG. 1. SIR for total number of tumours in all, RA and AS patients treated with
different anti-TNF agents. ADA: adalimumab; ETA: etanercept; INF: infliximab.
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Shared familial risk factors between cancer and RA patients
SIR, Twin and family studies show that susceptibility to RA has a
heritable basis, transmitted in part with some identified candidate
genes [1, 2]. As RA patients are at a risk of many cancers [3],
a question arises whether RA and cancer share heritable risk
factors, which has not been settled. Most studies have analysed the
links between RA and lymphohaemato-proliferative diseases,
providing some evidence on familial aggregation [4, 5]. Family
members of RA patients have not shown an overall risk of
lymphoma or cancer, but childhood Hodgkin disease has
been in excess and even other autoimmune conditions have been
associated with Hodgkin disease [4, 5]. No data have been
available on the risk of individual site-specific tumours in family
members of RA patients. In the present study, we used the
Swedish data resources on registered families and medically
diagnosed RA and cancer, all with a national coverage, to analyse
risks of cancer in family members of RA patients, with a specific
aim to settle the issue on possible shared genetic risk factors for
cancer and RA.
The RA research database was constructed by linking the
Multigeneration Register (persons born in Sweden in 1932 and
later are linked to their parents) to the Swedish Hospital
Discharge Register (all hospital discharges with dates of
hospitalization and diagnoses since the 1960s with a complete
nation-wide coverage since 1986) and to the nation-wide Swedish
Cancer Registry (cancers from 1958 to 2004). The database
contains 11.5 million individuals among whom a total of 50 354
RA patients were identified. Details of the data sources and
methods can be found in our previous publications [5, 6]. In the
analysis of familial risks, parents were considered probands and
standardized incidence ratios (SIRs) were calculated for offspring,
who were followed until 31 December 2004. SIRs were calculated
as the ratio of observed (O) to expected (E) number of cases.
The expected number of cases was calculated for age (5-yr
groups), sex, period (5-yr groups), region and socioeconomic
status-specific SIRs.
Familial risks between RA and cancer were examined in two
ways (Table 1): risk of a specific cancer in offspring whose parents
were diagnosed with RA (excluding parent–offspring pairs with
the concordant cancers), and risk of RA in offspring whose
parents were diagnosed with a specific cancer (excluding parent–
offspring pairs with RA). We wanted to make sure that we
examined familial risks between discordant diseases, RA and a
specific cancer, by excluding families with concordant disease.
However, familial diseases were so rare that the exclusions did not
change the results. The SIR for no offspring cancer was changed
when a parent was diagnosed with RA. SIRs for RA were
decreased in offspring whose parents were diagnosed with
tumours of the oesophagus (0.53), colon (0.85), breast (0.84)
and ovary (0.61). The analysis was repeated for siblings, which
Rheumatology key message
 Risk of malignancy with the use of TNF antagonists might differ in
different disease states (i.e. RA, SpAs), and perhaps with the use
of different anti-TNF agents.
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